These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 16696487)

  • 1. AAPM TG-43U1 formalism adaptation and monte carlo dosimetry simulations of multiple-radionuclide brachytherapy sources.
    Nuttens VE; Lucas S
    Med Phys; 2006 Apr; 33(4):1101-7. PubMed ID: 16696487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brachytherapy dosimetry parameters calculated for a new 103Pd source.
    Rivard MJ; Melhus CS; Kirk BL
    Med Phys; 2004 Sep; 31(9):2466-70. PubMed ID: 15487726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recommendations of the American Association of Physicists in Medicine regarding the impact of implementing the 2004 task group 43 report on dose specification for 103Pd and 125I interstitial brachytherapy.
    Williamson JF; Butler W; Dewerd LA; Huq MS; Ibbott GS; Mitch MG; Nath R; Rivard MJ; Todor D;
    Med Phys; 2005 May; 32(5):1424-39. PubMed ID: 15984693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dosimetric characteristics of the new RadioCoil 103Pd wire line source for use in permanent brachytherapy implants.
    Meigooni AS; Zhang H; Clark JR; Rachabatthula V; Koona RA
    Med Phys; 2004 Nov; 31(11):3095-105. PubMed ID: 15587663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monte Carlo dosimetry for 125I and 103Pd eye plaque brachytherapy with various seed models.
    Thomson RM; Rogers DW
    Med Phys; 2010 Jan; 37(1):368-76. PubMed ID: 20175499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update of AAPM Task Group No. 43 Report: A revised AAPM protocol for brachytherapy dose calculations.
    Rivard MJ; Coursey BM; DeWerd LA; Hanson WF; Huq MS; Ibbott GS; Mitch MG; Nath R; Williamson JF
    Med Phys; 2004 Mar; 31(3):633-74. PubMed ID: 15070264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dosimetry of (125)I and (103)Pd COMS eye plaques for intraocular tumors: report of Task Group 129 by the AAPM and ABS.
    Chiu-Tsao ST; Astrahan MA; Finger PT; Followill DS; Meigooni AS; Melhus CS; Mourtada F; Napolitano ME; Nath R; Rivard MJ; Rogers DW; Thomson RM
    Med Phys; 2012 Oct; 39(10):6161-84. PubMed ID: 23039655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brachytherapy dosimetry of 125I and 103Pd sources using an updated cross section library for the MCNP Monte Carlo transport code.
    Bohm TD; DeLuca PM; DeWerd LA
    Med Phys; 2003 Apr; 30(4):701-11. PubMed ID: 12722822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monte Carlo dosimetry for 125I and 103Pd eye plaque brachytherapy.
    Thomson RM; Taylor RE; Rogers DW
    Med Phys; 2008 Dec; 35(12):5530-43. PubMed ID: 19175111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monte Carlo calculated TG-43 dosimetry parameters for the SeedLink 125Iodine brachytherapy system.
    Medich DC; Munro JJ
    Med Phys; 2003 Sep; 30(9):2503-8. PubMed ID: 14528972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calculated microdosimetric characteristics of 125I and 103Pd brachytherapy seeds at different depths in water.
    Wuu CS; Chen J
    Radiat Prot Dosimetry; 2006; 122(1-4):506-8. PubMed ID: 17189276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monte Carlo calculations and experimental measurements of dosimetric parameters of the IRA-103Pd brachytherapy source.
    Sadeghi M; Raisali G; Hosseini SH; Shavar A
    Med Phys; 2008 Apr; 35(4):1288-94. PubMed ID: 18491522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monte Carlo dosimetric characterization of the IsoAid ADVANTAGE 103Pd brachytherapy source.
    Sowards KT
    J Appl Clin Med Phys; 2007 Mar; 8(2):18-25. PubMed ID: 17592461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dosimetric study of a new polymer encapsulated palladium-103 seed.
    Bernard S; Vynckier S
    Phys Med Biol; 2005 Apr; 50(7):1493-504. PubMed ID: 15798339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dosimetric characteristic of a new 125I brachytherapy source.
    Sadeghi M; Khanmohammadi Z
    Radiat Prot Dosimetry; 2011 Nov; 147(3):451-6. PubMed ID: 21233096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monte Carlo calculation of dosimetry parameters for the IR08-103Pd brachytherapy source.
    Saidi P; Sadeghi M; Shirazi A; Tenreiro C
    Med Phys; 2010 Jun; 37(6):2509-15. PubMed ID: 20632562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accuracy assessment of the superposition principle for evaluating dose distributions of elongated and curved 103Pd and 192Ir brachytherapy sources.
    Bannon EA; Yang Y; Rivard MJ
    Med Phys; 2011 Jun; 38(6):2957-63. PubMed ID: 21815369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dosimetric effects of seed anisotropy and interseed attenuation for 103Pd and 125I prostate implants.
    Chibani O; Williamson JF; Todor D
    Med Phys; 2005 Aug; 32(8):2557-66. PubMed ID: 16193786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phantom size in brachytherapy source dosimetric studies.
    Pérez-Calatayud J; Granero D; Ballester F
    Med Phys; 2004 Jul; 31(7):2075-81. PubMed ID: 15305460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Theoretical and experimental determination of dosimetric characteristics for ADVANTAGE Pd-103 brachytherapy source.
    Meigooni AS; Dini SA; Awan SB; Dou K; Koona RA
    Appl Radiat Isot; 2006 Aug; 64(8):881-7. PubMed ID: 16713277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.